Improving treatment and understanding of food allergy
Therapeutic and Mechanistic Insights in Food Allergy
This project will try less frequent oral immunotherapy dosing to help people with food allergies stay protected while reducing daily burden and stomach problems.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11319775 on NIH RePORTER |
What this research studies
If you have a food allergy, this project will try whether taking oral immunotherapy less often than daily can keep you desensitized without the hassle of daily dosing. Participants who completed or are eligible for OIT will be followed over time to see if reduced-frequency maintenance dosing preserves protection and to watch for gastrointestinal problems like eosinophilic esophagitis. Researchers will measure immune markers and other biological signals to learn why some people maintain protection and others lose it, and they may compare different dose amounts and schedules. Care and monitoring will be provided at Stanford and affiliated clinics with close supervision for allergic reactions.
Who could benefit from this research
Good fit: People with diagnosed IgE-mediated food allergies who are current or past OIT participants or who are eligible for supervised OIT and willing to attend clinic visits are ideal candidates.
Not a fit: People with non-allergic food intolerances, uncontrolled eosinophilic gastrointestinal disease, or those unable to undergo supervised OIT are unlikely to benefit from this project.
Why it matters
Potential benefit: Could allow people to maintain protection from food allergies with fewer daily doses and fewer GI side effects.
How similar studies have performed: Oral immunotherapy has been shown to desensitize many patients, but reducing maintenance frequency while avoiding gastrointestinal complications is not yet reliably solved, so this approach builds on known successes but addresses an unmet need.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Sindher, Sayantani B. — Stanford University
- Study coordinator: Sindher, Sayantani B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.